Extensive studies have reported that DPY30 is overexpressed in many types of cancers, accompanied by increased H3K4me3 modification in cancer cells (Dixit et al., 2022; Gu et al., 2021; He et al., 2019; Hong et al., 2020; Lee et al., 2015; Shah et al., 2019; Yang et al., 2018; Zhang et al., 2018). This evidence concerns the gene DPY30 and cancer.